Modern Chinese Medicine Group (01643) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 145 million yuan, a decrease of 32.18% compared to the previous year. It reported an annual loss of 13.557 million yuan, contrasting with a profit of 9.67 million yuan in the same period last year. The basic loss per share was 2.05 cents. According to the announcement, the decline in revenue was primarily due to the loss of certain distributors. Among the factors, some of the group's best-selling products, such as Shan Mei Capsules, were not included in the national medical insurance list following healthcare reforms, leading to a drop in sales. Additionally, for other products that remained on the insurance list, reduced selling prices resulted in a decline in the overall gross profit margin.